Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Add as a preferred source on Google
UTRECHT, The Netherlands, Aug. 09, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
